Journals / Anestezi Dergisi / 2005 / Cilt: 13 - Sayı: 1

The use of botulinum toxin type A for pain management

Ağrı tedavisinde botulinum toksini tip A kullanımı

Pages
1–9
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review discusses the historical development of botox, its indications, contra-indications and side effects, the doses prescribed for various disorders, the mechanism of action and the use of botox in the treatment of pain conditions including headache, myofascial pain, and failed back surgery syndrome.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Botulinum toxin type A (BTX-A) has been used clinically for a number of disorders believed to be due to overactive striated or smooth muscles.
📊
Key Findings & Data:Bo tulünüm toxin has been shown to be effective for the treatment of various dystonic conditions such as blepharospasm, spasmodic torticollis, spasmodic dysphonia, and facial spasm.
💡
Conclusion & Impact:This review discusses the historical development of botox, its indications, contra-indications and side effects, the doses prescribed for various disorders, the mechanism of action and the use of botox in the treatment of pain conditions including headache, myofascial pain, and failed back surgery syndrome.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Ağrı · Yüz ağrısı · Botulinum toksini tip A

Abstract

Botulinum toxin type A (BTX-A) has been used clinically for a number of disorders believed to be due to overactive striated or smooth muscles. Bo tulünüm toxin has been shown to be effective for the treatment of various dystonic conditions such as blepharospasm, spasmodic torticollis, spasmodic dysphonia, and facial spasm. In addition to reducing muscle hyperactivity and spasm, BTX-A treatment often reduces the pain associated with cervical dystonia, achalasia, and rectal fissures. After irreversibly binding to presynaptic cholinergic nerve terminals, botulinum toxin prevents the release of acetylcholine, resulting in sustained muscle relaxation, which lasts until regeneration (reinnervation) of the nerve terminals is accomplished. Prelimi-nary evidence suggests that it may also be beneficial in the treatment of chronic low back pain associated with muscle spasm. This review discusses the historical development of botox, its indications, contra-indications and side effects, the doses prescribed for various disorders, the mechanism of action and the use of botox in the treatment of pain conditions including headache, myofascial pain, and failed back surgery syndrome.

Özet

Botulinum toksin tip A (BTX-A), iskelet veya düz kas aşırı aktivitesine bağlı olduğu düşünülen çeşitli hastalıklarda klinikte te-davi amaçlı kullanılmaktadır. BTX-A' nın, blefarospazm, spazma bağlı tortikollis ve fasiyel spazm gibi distoni ile seyreden çeşitli durumların tedavisinde etkinliği gösterilmiştir. Aşırı kas aktivitesi ve spazm tedavisinin yanısıra BTX-A, servikal distoni, akalazya ve rektal fissure bağlı ağrıları da azaltır. Botulinum toksini, presinaptik kolinerjik sinir uçlarına geri dönüşümsüz bağlandıktan sonra, asetilkolin salınımını engelleyerek uzun süreli kas gevşemesi ile sonuçlanır ve kas gevşemesi, sinir uçlarının rejenerasyonu tamamlanincaya kadar sürer. Yapılan çalışmalar Botulinum toksin tip A'nın kas spazmına bağlı kronik sırt ağrısının tedavisinde yararlı olacağını düşündürmektedir. Bu derlemede, botoksun tarihsel gelişimi, kullanım endikasyonları, kontrendikasyonları, çeşitli hastahklardaki kullanım dozu, etki mekanizması ve başağrısı, miyofasiyal ağrı, başarısız bel cerrahisi sendromu gibi ağrı yaratan çeşitli hastalıkların tedavisindeki kullanımına değinilmiştir.

🔖

Cite This Article

TÜZÜNER, F., AŞIK, İ. (2005). The use of botulinum toxin type A for pain management. Anestezi Dergisi, Cilt: 13 - Sayı: 1, 1–9. https://ajindex.com/articles/355663

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Wells C. Rationale for use of botulinum toxin type A in pain therapy. In: Botulinum toxin type A presentations at the 2nd World Congress of the World Institute of Pain, Istanbul, Turkey, 27-30 June 2001: 2-4
  2. Jankovic J, Brin ME Botulinum toksin: historical perspective and potential new indications. Muscle Nerve 1997, 20(suppl):S129-45
  3. Arnon SS, Schecter R, Inglesby TV, et al. Botulinum toksin as a biological weapon: medical and public health management. JAMA 2001,285:1059-70
  4. Coffield JA, Considine RB, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet M. (eds). Therapy with botulinum toxin. New York: Marcel Dekker, Inc., 1994:3-14
  5. Jankovic J, Brin ME Therapeutic uses of botulinum toxin. N Engl JMed 1991; 324:1186-94
  6. Childers MK, Wilson DJ, Simison D. Use of Botulinum toxin type A in Pain Management. In: Childers MK. (ed). Use of botulinum toxin, type A in pain management: a clinician's guide. Columbia: Book Masters, Inc 1999: 1-4
  7. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double blind placebo controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990; 40: 1213-8
  8. Anonymous. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1994; 44:2401-3
  9. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain. A randomized,-double-blind study. Neurology 2001; 56(10): 1290-3
  10. De Andres J. Clinical experience with botulinum toxin type A in back pain: a European perspective. In: Botulinum toxin type A presentations at the 2nd World Congress of the World Institute of Pain, Istanbul, Turkey, 27-30 June 2001: 5-7
  11. Royal M. Clinical experience with botulinum toxin type A in back pain: a US perspective. In: Botulinum toxin type A presentations at the 2nd World Congress of the World Institute of Pain, Istanbul, Turkey, 27-30 June 2001: 7-9
  12. ThungaR. Botulinum toxin for myofascial pain syndrome. In: Essentials of Pain Medicine and Regional Anesthesia. Churchill Livingstone, Philadelphia 1999; 92-5
  13. Mellanby J. Comparative activities of tetanus and botulinum toxins. Neuroscience 1984; 11: 16-23
  14. De Paiva A, Ashton A, Foran P, Schiavo G, Montecucco C, Doly J. Botulinum like type B and tetanus toxins fulfills criteria for being a zinc-dependen